Medical writing with expertise in oncology: communicating innovation
Elion Medical Communications is a leading provider of oncology medical writing services. From EGFR-TKIs, immunotherapy and CAR-T to ADC therapies, we bring oncology innovations to life. We create clear communication that disseminates important oncology technologies to healthcare professionals, patients and stakeholders.
Leading with experience
At Elion, we provide project management and expert oncology writing services to help researchers and biotech and pharmaceutical companies communicate emerging technologies with clarity and impact. Our team is dedicated to helping you advance the complex landscape of cancer treatments through clear and effective publications.
Our content complies with the latest publication and medical guidelines, ensuring your communications remain accurate and compliant.
Oncology Communications in Step with Emerging Discoveries
Today, scientific breakthrough in targeted immuno-based therapies progresses at an unprecedented speed.
Every breakthrough or discovery requires tailored communication that notifies clinicians, guides regulators and educates patients. At Elion, we translate the latest advances in EGFR tyrosine kinase inhibitors (EGFR-TKIs), chimeric antigen receptor T-cell (CAR-T) therapies and antibody–drug conjugates (ADCs) that promise to redefine the treatment of many cancer types.
Elion’s interest in oncology lies at the core of our identity and mission. Our very name stems from Nobel Prize-winning scientist — Dr
Gertrude Elion — who created the concept of rational drug design and sought to discover drugs that selectively targeted disease-causing
cells.
Oncology communications in step with emerging discoveries
Today, scientific breakthrough in targeted immuno-based therapies progresses at an unprecedented speed.
Every breakthrough or discovery requires tailored communication that notifies clinicians, guides regulators and educates patients. At Elion, we communicate the latest advances in epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), chimeric antigen receptor T-cell (CAR-T) therapies and antibody–drug conjugates (ADCs) that promise to redefine the treatment of many cancer types.
Elion’s interest in oncology lies at the core of our identity and mission. Our very name stems from Nobel Prize-winning scientist — Dr Gertrude Elion — who created the concept of rational drug design and sought to discover drugs that selectively targeted disease-causing cells.
‘...it was a matter of life and death to find treatments for diseases that hadn't been cured before.’
- Dr Gertrude Elion, 1988 Nobel Prize Laureate in Physiology or Medicine
Oncology therapies where we have made an impact
EGFR-TKIs
EGFR-TKIs are personalised targeted cancer medications that block EGFR signalling — a key driver of cell growth in certain tumours, especially non-small cell lung cancer (NSCLC). First- and second-generation TKIs paved the way for these therapies whereas third-generation agents like osimertinib have treated patients with resistance mutations such as T790M.
Programmed death ligand 1 (PD-L1) inhibitors
Some tumour cells express PD-L1 on their surface, which binds to PD-1 receptors on activated T-cells, delivering an ‘off’ signal that inhibits T-cell proliferation, cytokine production, and cytotoxic activity. PD-L1 inhibitors are antibodies that block this interaction and restore the immune system’s ability to recognise and attack tumour cells. Pembrolizumab is an example of a PD-1 inhibitor and durvalumab is a PD-L1 inhibitor.
Poly(ADP-ribose) polymerase (PARP) inhibitors
PARP inhibition prevents repair of single-strand DNA breaks that occur during cell replication. In cancer cells with defective homologous recombination repair (BRCA1 or BRCA2 mutations), DNA strand breaks accumulate, resulting in cell death. This process is known as synthetic lethality, where the combination of PARP inhibition and homologous recombination repair deficiency is lethal to cancer cells but not to healthy cells with intact DNA repair mechanisms.
Chimeric antigen receptor T-cell (CAR-T cell) therapies
CAR-T cell therapy has marked a major advance in the treatment of haematological cancers. By reprogramming a patient’s own T cells to attack cancer cells, CAR-T therapies, such as those targeting CD19, have led to responses in leukaemia and lymphoma. Today, research is focused on solid tumours, off-the-shelf (allogeneic) CAR-Ts and novel antigen targets.
Antibody–drug conjugates (ADCs)
ADCs are precision therapies that combine the targeting ability of antibodies with chemotherapy. ADCs deliver cytotoxic drugs directly to tumour cells, thus reducing systemic toxicity. Innovations in linker chemistry and payloads have expanded the ability of ADCs to target human epidermal growth factor receptor 2-positive disease as well as HER2-low and trophoblast cell surface antigen 2-expressing cancers.
Our work in oncology
Elion’s experts in oncology writing have extensive experience, including:
- primary and secondary publications for peer-reviewed journals
- educational materials on sequencing and resistance for healthcare professionals
- congress materials (abstracts, posters and oral presentations)
- medical affairs slide decks
- promotional marketing campaigns (email marketing, landing pages, digital sales aids, patient resources, leave-behinds)
- direct-to-consumer campaigns
- patient education and support materials
- advisory board reports.
Tumour types:
- Non-small-cell lung cancer
- Triple-negative breast cancer
- Muscle-invasive bladder cancer
- Head and neck cancer
- Neurofibromatosis type 1
- Ovarian cancer
- Non-Hodgkin lymphoma
- Colorectal cancer
- Urothelial carcinoma.
Our approach sets us apart
At Elion, we don’t just write documents; we project manage with leadership and insight.
We build partnerships with our pharmaceutical and medical communications agency partners based on trust and transparency. We take the time to understand your goals, ideas and timelines and stay with you every step of the way.
01
Define
Aligning on goals: we begin with a kick-off call and written brief to clarify objectives, timelines, audience, and deliverables. This ensures a shared understanding and smooth project setup.
02
Create
Developing content: we draft clear and engaging content in collaboration with your team. Messaging is grounded in evidence and tailored for your audience.
03
Refine
Reviewing and improving: we edit, fact check and integrate feedback to ensure accuracy, consistency and alignment with industry standards.
04
Enhance
Optimising outputs: we refine visuals, formatting and structure to maximise impact and engagement across all intended channels.
05
Deliver
Finalising and measuring impact: we prepare final deliverables, ready for submission, presentation or distribution. We can also help define success metrics and gather performance insights to inform future projects.
Expertise in oncology writing
At Elion, we work closely with healthcare organisations and pharmaceutical companies.
We understand the challenge of managing tight timelines, heavy workloads and fast-moving scientific data. Our experienced medical writers bring in-depth, up-to-date knowledge of targeted therapies and immuno-oncology to your communications.
Oncology writing FAQs
Yes, our team is well-versed in collaborating with international, cross-functional teams. We’re familiar with both global and local review and approval processes.
Absolutely. Our medical writers are experienced in assisting with publication planning and audience targeting strategies, helping you shape your oncology communications for maximum impact.
Our oncology materials speak directly to your intended audience without compromising scientific integrity.
Although AI tools can assist with drafting content, they often lack a proper understanding of complex oncology topics. At Elion, we support you by carefully checking and editing AI-generated content for scientific accuracy and coherence.
Project timelines can vary based on scope and complexity. Thanks to our global team and time zone advantage in New Zealand, we can work around the clock to deliver quickly — even quicker than in-house teams. This holds especially true for urgent projects.
We use internal review processes and cross-check all materials against source data, ensuring that every document maintains consistency with your messaging.
